DaVitaDVA
Recorded

DaVita 8th Annual Wolfe Research Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration31 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Justin LakeAnalyst of Healthcare Services

Part of the note? All right, good morning. My name is Justin Lake. I cover healthcare services here at Wolfe Research. Pleased to have with us on our second day of our Wolfe Healthcare Conference, DaVita and the company's CFO, Joel Ackerman. Joel, thanks for being with us.

Joel AckermanCFO

Thank you, Justin. It's a pleasure to be here.

Justin LakeAnalyst of Healthcare Services

Maybe before we get started, you just reported a pretty good third quarter, talked about a little bit of improvement in volume, patient census, a lot of things, kind of moving parts into 2027. You want to give us a one-minute kind of State of the Union update before we go into Q&A?

Joel AckermanCFO

Sure. Volume is number one on people's minds, for good reasons. The quarter was light on volume relative to our expectations by about 20 basis points. You can think of volume as being census-driven and then missed treatment-driven. Census being the more important component because it's permanent and it drives next quarter and next year, and missed treatment being a little bit more of temporary variability. And we missed because of missed treatment rate. Census came in actually a little bit better than expected, and the missed treatment rate missed by about 20 basis points. It was 20 basis points worse than expectations and about 20 basis points worse than Q3 of last year. You can split missed treatment rate into two components, which are roughly equal in scale in a normal quarter. Patients' missed treatments because they're in the hospital. They're not missing dialysis, but they're getting dialysis in the hospital.

Joel AckermanCFO

The other is what we call no-shows. Patients don't show up for their treatment. A lot of that is because they're not feeling well, and there can be other factors, for example, transportation problems, some of which we can reschedule, some of which we can't. This was missed treatment rate related to hospitalizations, and what we saw was, I think, what was seen broadly in the U.S., which is hospitalizations were up in Q3 of 2026 versus Q3 of 2025. We saw that in the public reporting of the large hospital companies. We certainly saw it in Kaufman Hall data and then in CDC data as well. We don't think there was anything particular to our population. It was just a broader impact. Our assumptions for next quarter is that missed treatment rate normalizes to the typical seasonal pattern.

Joel AckermanCFO

To be clear, what that means is our assumption is missed treatment rate will be higher in Q4 than it was in Q3, which is what we see virtually every year, and that's largely about seasonal patterns related to flu. But we're not anticipating the spread between Q4 of 2026 and Q4 of 2025. So, missed treatment rate goes up for Q4, but reverts to a normal pattern year over year. That's the big volume story. On the other big topic we talk about is mortality. We continue to feel good about the progress we've seen on mortality from a lot of the clinical initiatives we've implemented, and the biggest opportunity for mortality improvement over the next few years is from a new modality that we just introduced to help clear middle molecules. As you'll remember, dialysis is about two things.

Joel AckermanCFO

Our chief medical officer likes to talk about it as a washing machine and a dryer. The dryer is removing fluids, and fluid management is an important clinical initiative we have, and we're feeling good about that. The washing machine is about taking toxins out of the blood. The challenge with taking toxins out of the blood is you got to take out the bad stuff and leave in the good stuff. The good stuff generally being proteins or albumin. Historically, the way you do that is you make the filter small enough so the small toxins come out and proteins, which are large, stay in the blood. That leaves a category of toxins, they call them middle molecules, that historically have not been cleared well because the filter was too fine.

Joel AckermanCFO

We've now got new technologies, both new dialyzers as well as a new machine that can do that. We've leaned in on the new dialyzers to do this. We've done a really exciting pilot over the last few months that was very successful with patients, with our teammates, and in particular, with our physicians. We're now rolling out those dialyzers to all our clinics, and we expect to have them available for the vast majority of our eligible patients in November. So, that, I'm coming back to volume because that, we believe, based on a lot of good clinical evidence, will drive improvements over mortality over the next few years, and that's really the next biggest opportunity to drive volume improvement.

Justin LakeAnalyst of Healthcare Services

Got it. I know you have some headwinds and tailwinds going into the fourth quarter on volume specifically. You talked about the improving census in the third quarter that should run right into the fourth quarter. You also have a calendar headwind Yes in the fourth quarter that is pretty material.

Justin LakeAnalyst of Healthcare Services

If I think about instead of year-over-year, if I think about sequentially, is there a meaningful step-down just because of the calendar, third quarter to the fourth quarter in volume, or is it pretty flat?

Joel AckermanCFO

No, there will be a very meaningful step-down. The calendar issue is a few things. One is how many treatment days there are in the quarter. When New Year's Day falls is important. Remember, we are talking about basis points worth of volume, which is why little things like that matter, and how many Monday, Wednesday, and Fridays versus Tuesday and Thursdays and Saturdays there are in the quarter. We do more treatments on Monday, Wednesday, Friday than Tuesday, Thursday, Saturday. Q3 had a calendar tailwind in 2026 versus 2025 of about 65 basis points. I am looking at my team here to make sure I get my numbers right. So, benefited by that, and Q4 actually has a headwind of almost 100 basis points year-over-year.

Joel AckermanCFO

What we would expect in treatment days would be something around flattish, maybe even a little negative, and what we recommend to investors is the best way to model it is treatments per normalized day. We disclose how many normalized days there are in any quarter, and that should be the number that tends to look smoother because it removes this whole calendar impact.

Justin LakeAnalyst of Healthcare Services

Got it. Treatments down somewhat materially Q3 to Q4. One of the questions I have gotten is, from a guidance perspective, looks like your OI at the midpoint needs to be up $30 million, give or take, 3Q to 4Q. I think a lot of that is expected to come outside. I think all of it is expected to come outside of the dialysis business, right?

Justin LakeAnalyst of Healthcare Services

Right. Your IKC business- IKC, exactly.

Justin LakeAnalyst of Healthcare Services

has a great fourth quarter, typically, right? You see a lot of benefit there. Maybe a little bit of sequential headwind from the international business. Q3 there was amazingly good.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day